Your browser doesn't support javascript.
loading
Patterns of progression in patients treated for immuno-oncology antibodies combination.
Bernard-Tessier, Alice; Baldini, Capucine; Castanon, Eduardo; Martin, Patricia; Champiat, Stéphane; Hollebecque, Antoine; Postel-Vinay, Sophie; Varga, Andreea; Bahleda, Rastilav; Gazzah, Anas; Michot, Jean-Marie; Ribrag, Vincent; Armand, Jean-Pierre; Marabelle, Aurélien; Soria, Jean-Charles; Massard, Christophe; Ammari, Samy.
Afiliación
  • Bernard-Tessier A; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Baldini C; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Castanon E; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Martin P; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Champiat S; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Hollebecque A; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Postel-Vinay S; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Varga A; ATIP-Avenir, INSERM U981, Gustave Roussy, Villejuif, 94805, France.
  • Bahleda R; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Gazzah A; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Michot JM; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Ribrag V; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Armand JP; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Marabelle A; Université Paris-Saclay, Villejuif, 94805, France.
  • Soria JC; INSERM, U1170, Gustave Roussy, Villejuif, 94805, France.
  • Massard C; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
  • Ammari S; Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, 94805, France.
Cancer Immunol Immunother ; 70(1): 221-232, 2021 Jan.
Article en En | MEDLINE | ID: mdl-32700090
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antineoplásicos Inmunológicos / Melanoma / Anticuerpos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antineoplásicos Inmunológicos / Melanoma / Anticuerpos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Francia